[A20-44] Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2020
Project no.:
A20-44
Commission:
Commission awarded on 06.05.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Adults with Behçet’s disease and oral ulcers who are candidates for systemic therapy
Result of dossier assessment:
Added benefit not proven due to lack of suitable comparative data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-09 | Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |